Abstract
Evaluation of airborne infection risk with spatial and temporal resolutions is indispensable for the design of proper interventions fighting infectious respiratory diseases (e.g., COVID-19), because the distribution of aerosol contagions is both spatially and temporally non-uniform. However, the well-recognized Wells-Riley model and modified Wells-Riley model (i.e., the rebreathed-fraction model) are limited to the well-mixed condition and unable to evaluate airborne infection risk spatially and temporally, which could result in overestimation or underestimation of airborne infection risk. This study proposes a dilution-based evaluation method for airborne infection risk. The method proposed is benchmarked by the Wells-Riley model and modified Wells-Riley model, which indicates that the method proposed is a thorough expansion of the Wells-Riley model for evaluation of airborne infection risk with both spatial and temporal resolutions. Experiments in a mock hospital ward also demonstrate that the method proposed effectively evaluates the airborne infection risk both spatially and temporally.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work described in this paper is supported by the National Natural Science Foundation of China (Project No. 51878585). The help of Ms. Yalin Lu in the experiments is highly appreciated.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB is necessary.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available in the manuscript.